Evaluation of the neuromuscular blocking effect of Arduan.
D000293:Adolescent; D000328:Adult; D000368:Aged; D015113:Androstane-3,17-diol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000732:Androstanols / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005702:Galantamine / Q000494:pharmacology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000494:pharmacology; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009469:Neuromuscular Junction / Q000187:drug effects*; D017300:Pipecuronium; D010879:Piperazines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013997:Time Factors
D000732:Androstanols; D009466:Neuromuscular Blocking Agents; D010879:Piperazines; D005702:Galantamine; D017300:Pipecuronium; D015113:Androstane-3,17-diol; D009388:Neostigmine